Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: How long should patients be treated?

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 11-12, 2005, Pages 1107-1113

  Domenech E ^a   Hinojosa, J ^b   Nos, P ^c   Garcia Planella, E ^a   Cabre E ^a   Bernal, I ^a   Gassull, M A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b EAP Puerto de Sagunto   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 28844467220     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02670.x     Document Type: Article

References (16)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
2. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
4. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13.
5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
7. Farrell RJ, Alsahli M, Jeen Y-T, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomised controlled trial. Gastroenterology 2003; 124: 917-24.
8. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003; 124: 1140-5.
9. Mantzaris GJ, Ployzou P, Karagiannidis A, et al. A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid-dependent Crohn's disease. Gastroenterology 2004; 126(Suppl. 2): A-54.
10. Colombel J-F, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
11. Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stokholm County. Gut 2004; 53: 849-53.
12. Hommes D, Baert F, van Assche G, et al. A randomised controlled trial evaluating the ideal medical management for Crohn's disease: Top-down versus step-up strategies. Gastroenterology 2005; 128(Suppl. 2): A-577.
13. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003; 98: 332-9.
14. Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kam MA. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003; 17: 387-93.
15. Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002; 45: 39-46.
16. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the working party for the World Congresses of Gastroenterology, Vienna 1998. Infl Bowel Dis 2000; 5: 8-15.